Sanuwave Health (SNWV) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached a record $7.2 million, up 53% year-over-year, driven by increased UltraMIST system sales and higher average selling prices.

• Net income for Q2 2024 was $6.6 million, reversing a $7.3 million loss in Q2 2023, mainly due to changes in derivative liabilities, debt extinguishment, and a one-time patent license payment.

• Operating income improved to $2.0 million in Q2 2024, up $1.1 million year-over-year.

• Adjusted EBITDA for Q2 2024 was $1.5 million, up from $171,000 in Q2 2023.

• The company terminated its merger agreement with SEPA in June 2024 and is pursuing alternative uplisting and financial strategies.

Financial highlights

• Gross margin for Q2 2024 was 73%, slightly down from 74% in Q2 2023, despite higher manufacturing costs.

• Year-to-date net income was $2.2 million, compared to a net loss of $20.4 million in the first half of 2023.

• Adjusted EBITDA for the first half of 2024 was $1.4 million, versus a loss of $1.6 million in the first six months of 2023.

• Cash at June 30, 2024 was $2.5 million, up from $1.8 million at year-end 2023.

• Other income in Q2 2024 included a $5.3 million gain on extinguishment of debt and a $2.5 million one-time patent license payment.

Outlook and guidance

• Q3 2024 revenue is forecasted to rise 65%-75% year-over-year, reaching $8–8.5 million, with gross margin expected to remain in the mid-70% range.

• Management plans to devote substantial resources to commercializing UltraMIST and PACE systems, requiring additional capital.

• The company is seeking new capital through equity, convertible securities, or debt, but warns of potential dilution and uncertainty in raising funds.

• Continued hiring of sales staff and focus on rapid, profitable growth are planned.